Health ❯ Healthcare ❯ Biotechnology

Drug Development

Clinical Trials Oncology Inflammatory Diseases Rare Diseases Obesity Treatments Therapeutics Gene Therapy Obesity Treatment PCSK9 Inhibitors Petosemtamab

Lakewood-Amedex Says Nu-3 Did Not Induce Resistance in Lab Tests as Stock Soars

Preclinical data point to a high resistance barrier for a membrane-disrupting antibiotic pending clinical trials or funding decisions.

FDA Grants Accelerated Approval to Trutakna for IgA Nephropathy

Abivax Prices $800 Million ADS Offering and Nears $11 Billion Valuation

Biogen to Buy RayThera for Up to $1 Billion

Atara Investors Get May 22 Deadline to Seek Lead Role in Securities Suit

FDA Grants Orphan Drug Status to Immutep’s Efti for Soft Tissue Sarcoma

SCYNEXIS Acquires Poxel’s PXL-770 for ADPKD, Plans 2026 Phase 2 Trial

FDA Grants Accelerated Approval to Avlayah for Neurologic Manifestations of Hunter Syndrome

Sanofi Licenses Kali’s Tri-Specific Autoimmune Antibody KT501 in Deal Worth Up to $1.23 Billion

Arvinas’ ARV-102 Hits >50% LRRK2 Degradation in Phase 1 Parkinson’s Trial

Novo Nordisk Licenses Vivtex Platform in $2.1 Billion Push for Oral Obesity and Diabetes Drugs

Eli Lilly to Acquire Ventyx Biosciences for $1.2 Billion in Bet on Oral NLRP3 Drugs

Jan. 16 Deadline Nears in Skye Bioscience Investor Class Actions

MoonLake Immunotherapeutics Investors Face Lead‑Plaintiff Deadline in Securities Fraud Suits

Skye Bioscience Investors Pressed to Seek Lead Role After Class Action Filing

Sofinnova Closes €650 Million Capital XI to Back Early-Stage Biotech and Medtech

MoonLake Investors Courted for Lead Role in SDNY Securities Case After SLK Trial Collapse

Braveheart Bio Launches With $185 Million Series A to Advance HCM Drug

Helex Raises $3.5 Million to Advance Kidney-Targeted Gene Therapies

MoonLake Investors Face Dec. 15 Lead-Plaintiff Deadline in SDNY Securities Case